secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2026-05-13T11:23:09+00:00
Accession:  0001104659-26-059780
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Q1 2026 net loss $26.1M; CARDAMYST launch yields $0.2M revenue, 600 scripts
--------------------------------------------------------------------------------

- Product revenue of $0.2M from first quarter of CARDAMYST launch; no prior-year revenue.
- Net loss $26.1M ($0.20 per share) vs $20.8M ($0.31) a year ago; cash $184.2M, runway into H2 2027.
- ~600 scripts filled for 560 PSVT patients; ~400 unique prescribers as of April.
- Express Scripts national formulary coverage effective March 27, 2026; >25% of commercially insured lives covered.
- Phase 3 AFib-RVR trial initiated; first patient enrollment expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/0001104659-26-059780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/tm2614433d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-059780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer